Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL877542 | 0.80 | KMT2A (0.41) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL877980 | 0.75 | TRPM8 (0.33) | MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL16125119 | 0.67 | SORD (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL9900908 | 0.66 | HPGD (0.39) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL12128393 | 0.65 | HTT (0.47) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL3024635 | 0.64 | SMN1; SMN2 (0.35) | SMN1; SMN2MEN1KMT2AHPGDNPSR1 | |
| SCHEMBL20603251 | 0.64 | TP53 (0.64) | RAB9ASMN1; SMN2NPC1TP53ALDH1A1 | |
| SCHEMBL25360339 | 0.64 | MEN1 (0.37) | SMN1; SMN2MEN1KMT2ANPSR1KDM4E | |
| SCHEMBL959784 | 0.64 | MEN1 (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL535681 | 0.64 | HTT (0.36) | SMN1; SMN2MEN1KMT2ANPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619207-B1 | 4,7-Dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-12 | — | — | EP | disclosed |
| US-8609660-B2 | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-17 | — | — | US | disclosed |
| EP-2619207-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | Janssen Pharmaceutica, N.V. (BE) | 2013-07-31 | — | — | EP | disclosed |
| US-20130190318-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012038438-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190318-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | RAB9A 2001/4885HDAC1 3166/4885SMN1; SMN2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.